NCT03636061View on ClinicalTrials.gov

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

August 15, 2018

Primary Completion Date

September 26, 2018

Study Completion Date

September 26, 2018

Conditions
Dry Eye Disease
Interventions
DRUG

OC-01 (varenicline) nasal spray

OC-01 (varenicline) nasal spray

DRUG

Placebo (vehicle) nasal spray

Placebo

Trial Locations (3)

46290

Indianapolis, Indianapolis

92663

Newport Beach, Newport Beach

01810

Andover, Andover

Sponsors
All Listed Sponsors
lead

Oyster Point Pharma, Inc.

INDUSTRY

NCT03636061 - Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease | Biotech Hunter | Biotech Hunter